BioSpace News Archive

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 14,000 shares of its common stock with an exercise price of $1.71, which is equal to the closing price of Gritstone’s common stock on September 6, 2023, the date of the grant.

Kiromic BioPharma announces that on September 12, 2023 it received formal notice from the NASDAQ Stock Market that the Company’s common stock has been suspended from trading on the Nasdaq Capital Market effective September 14, 2023, due to failure to demonstrate compliance with Listing Rule 5550.

Zomedica Corp. announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023, it has received formal notice from the NYSE American that it is not in compliance with the NYSE American’s continued listing standard set forth in Section 1003 of the NYSE American Company Guide because the Company’s common shares have been selling for a substantial period of time at a low price per share.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the positive outcome of the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

Adagio Medical, Inc. announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the Adagio vCLAS™ catheter system in the United States as part of the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia) clinical trial, NCT # NCT05675865.

BIOLASE, Inc., a global leader in dental lasers, announced the pricing of an underwritten public offering of 75,000 units, with each Unit consisting of one share of BIOLASE’s Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share, and one warrant to purchase one-half of one share of Series J Convertible Preferred Stock.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), the Company developing a new class of synthetic anti-infectives, announced today a capital raise of up to approximately $11 million before costs.

Science 37 announced today that it has been recognized in the Gartner Hype Cycle for Life Science Clinical Development, 2023.

Akili, Inc., a leading digital medicine company, announced its strategic plan to transition from a prescription to a non-prescription business model.

Lineage Cell Therapeutics, Inc. today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501.